page header

Contents  ·  Introduction  ·  Learning  Objectives  ·  Textbook  ·  Lectures  ·  Procedures  ·  Final Exam  ·  Library  ·  Laboratory  ·  Pharmacy  ·  Imaging  ·  Forms  ·  Videos  ·  About  ·  Contact Us>

Sodium thiosulfate 

Category:

  • Miscellaneous

Description:

  • Antidote, toxicology agent

Indications:

  • Acne vulgaris

  • Cyanide toxicity

  • Tinea versicolor

Contraindications:

  • Discontinue if irritation occurs while using topical formulation

  • Use in or around eyes

Precautions:

  • Pregnancy category C

Adverse Reactions (Side Effects):

  • diarrhea

Dosage:

Administered intravenously, topically (no commercial topical agents available)

Cyanide toxicity: 

  • Adult: 

    • Following administration of sodium nitrite (IV 300mg over 3-5 minutes), the usual dose of sodium thiosulfate is 12.5g (50ml of a 25% solution or 25ml of a 50% solution) over 10 minutes

  • Child: 

    • Following administration of sodium nitrite (0.15-0.33 ml/kg or 6-8 ml/square meter of a 3% solution; approximately 4.5-10 mg/kg), the suggested dose of sodium thiosulfate is 1.65 ml/kg or 28 ml/square meter of a 25% solution (412.5 mg/kg); 

    • alternatively, dosing can be based on the child’s hemoglobin (hg) concentration:

      • If hg concentration is 8g, initial dose IV 1.10 ml/kg as a 25% solution

      • If hg concentration is 10g, initial dose IV 1.35 ml/kg as a 25% solution

      • If hg concentration is 12g, initial dose IV 1.65 ml/kg as a 25% solution

      • If hg concentration is 14g, initial dose IV 1.95 ml/kg as a 25% solution

  • NOTE: If symptoms of cyanide toxicity recur, one half of each dose of sodium nitrite and sodium thiosulfate may be repeated after 30 minutes

Treatment of acne secondary to oily skin: 

  • Adults: 

    • Apply thin layer of sodium thiosulfate lotion twice daily after thoroughly washing affected area

Treatment of tinea versicolor: 

  • Adult and child: 

    • Apply a 20%-25% solution in a thin layer to affected areas twice daily.  

  • May take weeks or months of continued therapy after condition clears to prevent relapse

 


The information contained here is an abbreviated summary. For more detailed and complete information, consult the manufacturer's product information sheets or standard textbooks

Source: Operational Medicine 2001,  Health Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington, D.C., 20372-5300

This information is provided by The Brookside Associates.  The Brookside Associates, LLC. is a private organization, not affiliated with any governmental agency. The opinions presented here are those of the author and do not necessarily represent the opinions of the Brookside Associates or the Department of Defense. The presence of any advertising on these pages does not constitute an endorsement of that product or service by either the US Department of Defense or the Brookside Associates. All material presented here is unclassified.

C. 2009, 2014, All Rights Reserved

brookside associates logo

 

 

 

 

 

 

Advertise on this site